ProCE Banner Activity

MET-Targeted Therapies in Development: Capmatinib, Acquired Resistance to MET TKIs, and Next-Line Choices

Slideset Download
Download these slides for expert insights on MET-targeted therapies in development for MET-altered NSCLC, including capmatinib for METex14 mutation–positive disease.

Released: May 29, 2020

Expiration: May 28, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an independent grant from the Healthcare business of

Merck KGaA